Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma

Cancer Immunol Immunother. 2023 Dec;72(12):4471. doi: 10.1007/s00262-023-03575-4.

Lisa May Ling Tachiki^{1

2}, Daniel S Hippe³, Karly Williams Silva^{4

3}, Evan Thomas Hall^{4

3}, William McCamy⁴, Dane Fritzsche³, Andrea Perdue^{4

3}, Julia Majovski^{4

3}, Thomas Pulliam^{5

3}, Daniel A Goldstein⁶, Joshua Veatch^{4

3}, Joel Ho^{4

3}, Paul T Nghiem^{5

3}, John A Thompson^{4

3}, Shailender Bhatia^{7

8}

¹ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. ltachiki@uw.edu.
² Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ltachiki@uw.edu.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
⁵ Department of Medicine, Division of Dermatology, University of Washington, Seattle, WA, USA.
⁶ Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
⁷ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA. sbhatia@uw.edu.
⁸ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. sbhatia@uw.edu.

No abstract available

Publication types